The anticancer activity was validated on two cancer cell lines: lung A549 cell line and colorectal Caco-2 cell line, and through in silico receptor-ligand docking modeling using PI3Kδ and CatB proteins to impart insight into the level of the binding probability. Here, TYRP1 is linked to cancer.